Challenges
Datasets
Workspaces
Papers
Discussions
Leaderboard
Log inSign up
Challenges
Datasets
Workspaces
Papers
Discussions
Leaderboard
Blog
Job Board
Q3AS

© 2026 Aqora Quantum S.A.S.

TermsPrivacyLegal Notice

Entangling Oncology: Variational Quantum Eigensolver-Driven Optimization for Patient-Specific Multi-Modal Cancer Therapy Planning

Kelvin Chafachaipa, Richard Danda

Published Sep 1, 2025• 1 citation
Publisher

Abstract

Optimizing personalized cancer treatment plans that combine chemotherapy, radiation, and immunotherapy presents a complex challenge due to the need to balance efficacy with minimizing side effects across diverse patient profiles. This study introduces a novel hybrid quantum-classical framework leveraging the Variational Quantum Eigensolver (VQE) for multi-modal optimization. Treatment planning is formulated as a parameterized Hamiltonian, where the ground state corresponds to an optimal therapy regimen tailored to individual genomic and clinical data. The quantum VQE algorithm estimates ground state energy via quantum simulators, while classical optimizers iteratively refine circuit parameters. Benchmarking on synthetic datasets demonstrates that the hybrid approach enhances treatment personalization and computational efficiency over classical methods. Although current quantum hardware constraints limit immediate deployment, our findings validate the potential for quantum-enhanced optimization in clinical oncology. This research lays foundational groundwork for integrating near-term quantum algorithms into medical decision-making, with promising implications for improving cancer treatment outcomes and patient quality of life.

DOI
10.20944/preprints202509.0011.v1

Related papers

HYBRID QUANTUM ANNEALING–CLASSICAL OPTIMIZATION OF PERSONALIZED MULTI-DRUG CANCER THERAPY USING QUBO-BASED DIGITAL TWIN MODELING

Achile Solomon Egbunu, Peter Adetokunbo, Okedoye Akindele Michael

The optimization of multidrug cancer treatment schedules is a high-dimensional combinatorial optimization problem involving nonlinear tumor dynamics, pharmacokinetic interactions, and stringent toxicity constraints. When exploring large therapeutic search spaces, conventional optimization algorithms often exhibit limited scalability and become trapped in local optima. This simulation study proposes a hybrid quantum-classical optimization framework that employs QA to generate adaptive treatment schedules for precision oncology. The treatment scheduling problem is formulated as a quadratic unconstrained binary optimization (QUBO) model, which encodes drug combinations, dosing intervals, toxicity constraints, and synergistic interactions within an Ising Hamiltonian compatible with D-Wave quantum annealing hardware. Global combinatorial optimization is performed using a D-Wave Advantage quantum annealer, while sequential least squares programming refines continuous dosage parameters under pharmacokinetic and toxicity constraints. Tumor progression is represented using a modified Gompertz growth model coupled with first-order pharmacokinetic dynamics. The proposed framework was evaluated using synthetic Digital Twin datasets generated from clinically realistic pharmacokinetic and tumor growth parameters. Simulation results demonstrated a maximum tumor regression ratio of 0.98 ± 0.02, compared with 0.82 ± 0.05 for standard-of-care protocols, while maintaining a lower cumulative toxicity index (40 ± 5 versus 75 ± 8) and reducing optimization time to less than 2 s for 120-variable scheduling problems. The hybrid framework exhibited near-linear computational scalability and maintained robustness under stochastic dosage perturbations (TRR > 0.95 at σ = 0.25). However, predictive classification performance remained limited (AUC = 0.49), highlighting the need for validation using longitudinal clinical datasets and multimodal patient-specific data. These findings demonstrate the potential of hybrid quantum-classical optimization as a scalable computational framework for adaptive treatment scheduling and personalized precision oncology.

•Oct 22, 2026•0 citations

Variational Quantum Eigensolver for Clinical Biomarker Discovery: A Multi-Qubit Model

Juan Pablo Acuña González, Moisés Sánchez-Adame, Oscar Montiel

We formalize an inverse, data-conditioned variant of the Variational Quantum Eigensolver (VQE) for clinical biomarker discovery. Given patient-encoded quantum states, we construct a task-specific Hamiltonian whose coefficients are inferred from clinical associations and interpret its expectation value as a calibrated energy score for prognosis and treatment monitoring. The method integrates coefficient estimation, ansatz specification with basis rotations, commuting-group measurements, and a practical shot budget analysis. Evaluated on public infectious disease datasets under severe class imbalance, the approach yields consistent gains in balanced accuracy and precision–recall over strong classical baselines, with stability across random seeds and feature ablations. This variational energy scoring framework bridges Hamiltonian learning and clinical risk modeling, offering a compact, interpretable, and reproducible route to biomarker prioritization and decision support.

Axioms•Dec 27, 2025•2 citations

Data-Conditioned Variational Quantum Eigensolvers for Clinical Biomarker Discovery: Constructing Patient-Specific Hamiltonians from Medical Data

Filip Żarnowiec, Zbigniew Maciej Wawrzyniak, Ryszard S. Romaniuk

The variational quantum eigensolver (VQE) was at first designed as a hybrid quantum-classical method for finding the ground-state energies of molecules on noisy intermediate-scale quantum (NISQ) devices. Currently, however, there is a small but emerging line of research that takes the opposite approach: instead of minimizing the energy of a Hamiltonian which is derived from physical principles, the quantum state is determined according to an encoding of the patient’s clinical record, and the algorithm searches for a Hamiltonian whose ground state most closely matches that state. The resulting operator is regarded as a sparse and interpretable biomarker, and the expectation value of this operator is used as a calibrated clinical risk score. In this article, we examine this data-conditioned, or inverse, VQE approach. We begin by reiterating the standard VQE formalism, then restate the inverse objective along with its analytic solution for single-term Pauli Hamiltonians as given in the source. Additionally, we analyze the encoding, coefficient inference, measurement, and thresholding elements essential for a complete pipeline. A recent multi-qubit study involving a cohort with co-infection of HIV and tuberculosis is analyzed in detail as the most advanced example of this approach. We compare it with other related methods based on quantum kernels, variational quantum classifiers, and quantum-enhanced feature selection, and we place it within the current classification of quantum-enhanced biomarker discovery, where it does not belong in any of the existing categories. We then carry out a critical evaluation of the paradigm. The classical eigenvalue calculation within the search loop has an asymptotic scaling of O(8N), although at the two qubits that are actually used it is negligible. By restricting the search to single-term Pauli operators, it becomes possible to classically simulate the quantum expectation values, thereby nullifying the claims of quantum advantage while still preserving interpretability. The benefits reported are based on small, severely imbalanced, single-center cohorts and include no external validation or actual implementation on real hardware. Compared with the requirements that the quantum computing community is now moving towards for benchmark definitions, the published evaluation still does not yet satisfy most of the criteria currently proposed for application-level benchmarking, mainly because the classical and quantum contributions to the result are never separated. We conclude with a roadmap that specifies the particular conditions, from an evaluation-theoretic point of view, under which data-conditioned Hamiltonian learning could become a real application of quantum computing in precision medicine, before turning to algorithmic aspects.

International Journal of Electronics and Telecommunications•Oct 29, 2026•0 citations

Quantum-enhanced optimization for patient stratification in clinical trials

Laia Domingo, Christine Johnson

Clinical trials are notorious for their high failure rates and steep costs, leading to wasted time and resources spend, prolonged development timelines, and delayed patient access to new therapies. A key contributor to these failures is biological uncertainty, which complicates trial design and weakens the ability to detect true treatment effects. In particular, inadequate patient stratification often results in covariate imbalances across treatment arms, masking treatment effects and reducing statistical power, even when therapies are effective for specific patient subpopulations. This work presents an optimization-based, quantum-enhanced approach to patient stratification that explicitly minimizes covariate imbalance across numerical and categorical variables, without altering protocol design or trial endpoints. Using real clinical trial data, we demonstrate that hybrid quantum-classical optimization methods achieve high-quality stratification while scaling efficiently to larger cohorts. In our benchmark study, the quantum-enhanced pipeline delivered over a 100x improvement in computational efficiency compared to classical approaches, enabling faster iteration and practical deployment at scale. This report shows how improved stratification can lead to decision-relevant gains, including up to a fivefold increase in statistical significance in treatment effect estimation, reducing treatment-effect dilution and increasing trial sensitivity. Together, these results show that optimization-driven stratification can strengthen clinical trial design, improve confidence in downstream decisions, and reduce the risk of costly late-stage failure.

quant-pharXiv:2601.11413•Jan 19, 2026•1 citation

Adaptive Quantum Computing for Machine Learning via Variational Quantum Eigensolver Optimization

Jincheng Zhang

Variational Quantum Eigensolver (VQE) has emerged as a prominent hybrid quantum-classical algorithm for near-term quantum computing, particularly in applications like quantum machine learning. However, the performance of VQE is significantly constrained by the limitations of classical optimization methods employed to minimize the expectation value of the Hamiltonian. Traditional VQE approaches often suffer from slow convergence and sensitivity to initial conditions, particularly when dealing with complex, high-dimensional problems encountered in machine learning scenarios. This work introduces a novel adaptive quantum computing framework for VQE optimization, designed to dynamically adjust the quantum circuit parameters during the optimization process. By continuously monitoring the optimization progress and intelligently modifying the parameters, we aim to accelerate convergence and improve the robustness of VQE algorithms for machine learning tasks. The core idea is to shift from a static, fixed-parameter VQE to a dynamic, adaptive one. We explore various adaptive control strategies and demonstrate their potential to significantly reduce the number of iterations required to reach a solution, leading to improved computational efficiency and enabling VQE to tackle more complex machine learning problems within the constraints of current quantum hardware. The research focuses on the theoretical underpinnings and the design principles of this adaptive approach, laying the foundation for future implementations and experimental validation.

•Aug 28, 2026•0 citations

Quantum Machine Learning and Radiation Oncology

Sakshi Kumar, Mrittunjoy Guha Majumdar

Quantum machine learning (QML) leverages quantum phenomena such as superposition, entanglement, and interference to address computational challenges that are difficult for classical systems. In radiation oncology, where treatment planning, image guidance, adaptive replanning, and multi-modal data integration require high-dimensional optimisation and complex pattern recognition, QML may offer advantages in computational efficiency and representational capacity. This review systematically maps quantum algorithms to the clinical radiation oncology workflow. We outline foundational concepts in quantum computing, including complexity insights from the BQP class and practical constraints of the noisy intermediate-scale quantum (NISQ) era. The radiation oncology pipeline-from consultation and simulation to treatment planning, delivery, and follow-up-is analysed to identify computational bottlenecks where quantum methods could provide benefit. Current developments in quantum-enabled diagnostic modelling, quantum-inspired clinical decision support for precision radiotherapy, quantum reinforcement learning for adaptive treatment policies, and emerging concepts such as quantum digital twins are reviewed. Key challenges-including hardware limitations, barren plateaus, data encoding constraints, limited datasets, regulatory considerations, and the gap between theoretical speedups and clinical implementation-are critically examined. Finally, a three-horizon roadmap is proposed outlining near-term proof-of-concept research, mid-term integration with treatment planning systems, and long-term prospects for fault-tolerant quantum simulation in oncology.

•Mar 12, 2026•0 citations
Optimizing personalized cancer treatment plans that combine chemotherapy, radiation, and immunotherapy presents a complex challenge due to the need to balance efficacy with minimizing side effects across diverse patient profiles. This study introduces a novel hybrid quantum-classical framework leveraging the Variational Quantum Eigensolver (VQE) for multi-modal optimization. Treatment planning is formulated as a parameterized Hamiltonian, where the ground state corresponds to an optimal therapy regimen tailored to individual genomic and clinical data. The quantum VQE algorithm estimates ground state energy via quantum simulators, while classical optimizers iteratively refine circuit parameters. Benchmarking on synthetic datasets demonstrates that the hybrid approach enhances treatment personalization and computational efficiency over classical methods. Although current quantum hardware constraints limit immediate deployment, our findings validate the potential for quantum-enhanced optimization in clinical oncology. This research lays foundational groundwork for integrating near-term quantum algorithms into medical decision-making, with promising implications for improving cancer treatment outcomes and patient quality of life.
The optimization of multidrug cancer treatment schedules is a high-dimensional combinatorial optimization problem involving nonlinear tumor dynamics, pharmacokinetic interactions, and stringent toxicity constraints. When exploring large therapeutic search spaces, conventional optimization algorithms often exhibit limited scalability and become trapped in local optima. This simulation study proposes a hybrid quantum-classical optimization framework that employs QA to generate adaptive treatment schedules for precision oncology. The treatment scheduling problem is formulated as a quadratic unconstrained binary optimization (QUBO) model, which encodes drug combinations, dosing intervals, toxicity constraints, and synergistic interactions within an Ising Hamiltonian compatible with D-Wave quantum annealing hardware. Global combinatorial optimization is performed using a D-Wave Advantage quantum annealer, while sequential least squares programming refines continuous dosage parameters under pharmacokinetic and toxicity constraints. Tumor progression is represented using a modified Gompertz growth model coupled with first-order pharmacokinetic dynamics. The proposed framework was evaluated using synthetic Digital Twin datasets generated from clinically realistic pharmacokinetic and tumor growth parameters. Simulation results demonstrated a maximum tumor regression ratio of 0.98 ± 0.02, compared with 0.82 ± 0.05 for standard-of-care protocols, while maintaining a lower cumulative toxicity index (40 ± 5 versus 75 ± 8) and reducing optimization time to less than 2 s for 120-variable scheduling problems. The hybrid framework exhibited near-linear computational scalability and maintained robustness under stochastic dosage perturbations (TRR > 0.95 at σ = 0.25). However, predictive classification performance remained limited (AUC = 0.49), highlighting the need for validation using longitudinal clinical datasets and multimodal patient-specific data. These findings demonstrate the potential of hybrid quantum-classical optimization as a scalable computational framework for adaptive treatment scheduling and personalized precision oncology.
We formalize an inverse, data-conditioned variant of the Variational Quantum Eigensolver (VQE) for clinical biomarker discovery. Given patient-encoded quantum states, we construct a task-specific Hamiltonian whose coefficients are inferred from clinical associations and interpret its expectation value as a calibrated energy score for prognosis and treatment monitoring. The method integrates coefficient estimation, ansatz specification with basis rotations, commuting-group measurements, and a practical shot budget analysis. Evaluated on public infectious disease datasets under severe class imbalance, the approach yields consistent gains in balanced accuracy and precision–recall over strong classical baselines, with stability across random seeds and feature ablations. This variational energy scoring framework bridges Hamiltonian learning and clinical risk modeling, offering a compact, interpretable, and reproducible route to biomarker prioritization and decision support.
The variational quantum eigensolver (VQE) was at first designed as a hybrid quantum-classical method for finding the ground-state energies of molecules on noisy intermediate-scale quantum (NISQ) devices. Currently, however, there is a small but emerging line of research that takes the opposite approach: instead of minimizing the energy of a Hamiltonian which is derived from physical principles, the quantum state is determined according to an encoding of the patient’s clinical record, and the algorithm searches for a Hamiltonian whose ground state most closely matches that state. The resulting operator is regarded as a sparse and interpretable biomarker, and the expectation value of this operator is used as a calibrated clinical risk score. In this article, we examine this data-conditioned, or inverse, VQE approach. We begin by reiterating the standard VQE formalism, then restate the inverse objective along with its analytic solution for single-term Pauli Hamiltonians as given in the source. Additionally, we analyze the encoding, coefficient inference, measurement, and thresholding elements essential for a complete pipeline. A recent multi-qubit study involving a cohort with co-infection of HIV and tuberculosis is analyzed in detail as the most advanced example of this approach. We compare it with other related methods based on quantum kernels, variational quantum classifiers, and quantum-enhanced feature selection, and we place it within the current classification of quantum-enhanced biomarker discovery, where it does not belong in any of the existing categories. We then carry out a critical evaluation of the paradigm. The classical eigenvalue calculation within the search loop has an asymptotic scaling of O(8N), although at the two qubits that are actually used it is negligible. By restricting the search to single-term Pauli operators, it becomes possible to classically simulate the quantum expectation values, thereby nullifying the claims of quantum advantage while still preserving interpretability. The benefits reported are based on small, severely imbalanced, single-center cohorts and include no external validation or actual implementation on real hardware. Compared with the requirements that the quantum computing community is now moving towards for benchmark definitions, the published evaluation still does not yet satisfy most of the criteria currently proposed for application-level benchmarking, mainly because the classical and quantum contributions to the result are never separated. We conclude with a roadmap that specifies the particular conditions, from an evaluation-theoretic point of view, under which data-conditioned Hamiltonian learning could become a real application of quantum computing in precision medicine, before turning to algorithmic aspects.
Clinical trials are notorious for their high failure rates and steep costs, leading to wasted time and resources spend, prolonged development timelines, and delayed patient access to new therapies. A key contributor to these failures is biological uncertainty, which complicates trial design and weakens the ability to detect true treatment effects. In particular, inadequate patient stratification often results in covariate imbalances across treatment arms, masking treatment effects and reducing statistical power, even when therapies are effective for specific patient subpopulations. This work presents an optimization-based, quantum-enhanced approach to patient stratification that explicitly minimizes covariate imbalance across numerical and categorical variables, without altering protocol design or trial endpoints. Using real clinical trial data, we demonstrate that hybrid quantum-classical optimization methods achieve high-quality stratification while scaling efficiently to larger cohorts. In our benchmark study, the quantum-enhanced pipeline delivered over a 100x improvement in computational efficiency compared to classical approaches, enabling faster iteration and practical deployment at scale. This report shows how improved stratification can lead to decision-relevant gains, including up to a fivefold increase in statistical significance in treatment effect estimation, reducing treatment-effect dilution and increasing trial sensitivity. Together, these results show that optimization-driven stratification can strengthen clinical trial design, improve confidence in downstream decisions, and reduce the risk of costly late-stage failure.
Variational Quantum Eigensolver (VQE) has emerged as a prominent hybrid quantum-classical algorithm for near-term quantum computing, particularly in applications like quantum machine learning. However, the performance of VQE is significantly constrained by the limitations of classical optimization methods employed to minimize the expectation value of the Hamiltonian. Traditional VQE approaches often suffer from slow convergence and sensitivity to initial conditions, particularly when dealing with complex, high-dimensional problems encountered in machine learning scenarios. This work introduces a novel adaptive quantum computing framework for VQE optimization, designed to dynamically adjust the quantum circuit parameters during the optimization process. By continuously monitoring the optimization progress and intelligently modifying the parameters, we aim to accelerate convergence and improve the robustness of VQE algorithms for machine learning tasks. The core idea is to shift from a static, fixed-parameter VQE to a dynamic, adaptive one. We explore various adaptive control strategies and demonstrate their potential to significantly reduce the number of iterations required to reach a solution, leading to improved computational efficiency and enabling VQE to tackle more complex machine learning problems within the constraints of current quantum hardware. The research focuses on the theoretical underpinnings and the design principles of this adaptive approach, laying the foundation for future implementations and experimental validation.
Quantum machine learning (QML) leverages quantum phenomena such as superposition, entanglement, and interference to address computational challenges that are difficult for classical systems. In radiation oncology, where treatment planning, image guidance, adaptive replanning, and multi-modal data integration require high-dimensional optimisation and complex pattern recognition, QML may offer advantages in computational efficiency and representational capacity. This review systematically maps quantum algorithms to the clinical radiation oncology workflow. We outline foundational concepts in quantum computing, including complexity insights from the BQP class and practical constraints of the noisy intermediate-scale quantum (NISQ) era. The radiation oncology pipeline-from consultation and simulation to treatment planning, delivery, and follow-up-is analysed to identify computational bottlenecks where quantum methods could provide benefit. Current developments in quantum-enabled diagnostic modelling, quantum-inspired clinical decision support for precision radiotherapy, quantum reinforcement learning for adaptive treatment policies, and emerging concepts such as quantum digital twins are reviewed. Key challenges-including hardware limitations, barren plateaus, data encoding constraints, limited datasets, regulatory considerations, and the gap between theoretical speedups and clinical implementation-are critically examined. Finally, a three-horizon roadmap is proposed outlining near-term proof-of-concept research, mid-term integration with treatment planning systems, and long-term prospects for fault-tolerant quantum simulation in oncology.